Molnupiravir là gì ?

What is molnupiravir?

It is an oral capsule drug developed by an American pharmaceutical company (Merch&Co, MSD). Results of a phase 3 clinical trial in 2021 suggest it could reduce the risk of hospitalization or death from Covid-19 by about 30%.

Licenses for use in countries
Country Licenses In addition to the emergency use authorization of Molnupiravir (EUA) from the US Food and Drug Administration (FDA) by the end of 2021, a conditional marketing authorization has been issued. approved in the UK, and the European Medicines Agency (EMA) has also issued positive scientific advice in favor of emergency use in EU member states prior to marketing authorization.

Taiwan also adopted the EUA on January 13, 2022.
On February 17, 2022, the Drug Administration of Vietnam Ministry of Health issued an urgent dispatch to appoint Vietnamese companies to produce 3 drugs with Molnupiravir ingredients.

User object
Each course of treatment for 5 days, 12 hours apart take 2 tablets of 400mg, including 20 tablets.

For F0 (tested positive) use only. Not licensed to use to prevent Covid-19.
Not suitable for minors, may affect the development of bones and cartilage.
Pregnant women should not use it, it can harm the unborn baby.
If you are planning to become pregnant, adult men and women should use contraception for 3 months after treatment.

Side effects
Due to the limited clinical trial experience of Molnupiravir, all possible risks have not been fully determined at this time,
diarrhea, nausea, dizziness etc., or other serious and undesirable side effects may also occur..

Currently, Molnupiravir is only used for F0 (tested positive), for preventive use or for adolescents, pregnant women, and groups planning pregnancy should still use other drugs. More clinical trial information is still needed to finalize the drug's effectiveness and side effects.


  1. 世紀瘟疫又有特效藥抗新冠病毒口服藥molnupiravir將申請緊急上市-風傳媒 (
  2. 台灣成亞洲第2國取得默沙東口服藥 - - 自由健康網 (
  3. 默沙東新冠口服藥來了 3種人是禁忌青少年可用的輝瑞新藥也快到了健康2.0 (
  4. 《FDA第二款口服!緊急使用核准默克Molnupiravir 治療新冠輕中症患者: 出現症狀五天內持續五天治療 但懷孕者請避開! - 生技投資第一站-Genet 觀點 (
  5. 附件2_公費COVID-19治療用口服抗病毒藥物領用方案_1110126制定.pdf (
  6. Pharmacity distributes drugs containing the active ingredient Molnupiravir (
  7. Mild F0s will soon access antiviral drugs 300,000 VND/dose (
  8. Boston Pharma is officially licensed to market Molravir 400 (active ingredient molnupiravir)
Back to blog

Leave a comment